What is STAMPEDE and why are we doing this study?

STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) is a large clinical trial that aims to assess new treatment approaches for people affected by high-risk prostate cancer. The STAMPEDE trial has now completed recruitment. The final day of patient randomisation was completed on 31st March 2023.

Since 2005 the trial has tested many different ways of treating prostate cancer and some results are now already known. Each new or alternative treatment has been compared with the current standard approach, referred to as a "comparison". Almost 12,000 participants joined the trial, with answers becoming available throughout the trial as information on life expectancy and disease control rates were gathered and compared.

All trial participants have been asked whether they would like to join some of the sub-studies being run alongside the trial. These aim to address several additional research questions such as what effect each treatment has on quality-of-life (QL), and which provides the greater value for money for the health service. Some sub-studies are focused on improving our understanding of the biology of prostate cancer. For example, can genetic changes be identified in prostate cancer cells that could predict which treatments might work best and may explain why some treatments stop working?

What have the results of the trial shown so far?

In the past STAMPEDE also tested whether adding docetaxel chemotherapy, zoledronic acid, or celecoxib, alone or in combination, was beneficial in controlling prostate cancer growth and improving life expectancy. Recruitment has been completed to all of these original treatment groups, the results have been presented.

The addition of docetaxel was shown to benefit patients and this has led to a change in clinical practice. See the summary of results that we prepared for the STAMPEDE participants letting them know about the details of these results STAMPEDE participant summary 2016

In results presented in June 2017, the addition of abiraterone to androgen-deprivation therapy has also been shown to be beneficial. See the summary of results that we prepared for the STAMPEDE participants letting them know about the details of these results.

In results presented in October 2018, the provision of radiotherapy to patients with metastatic prostate cancer, resulted in a substantial improvement in survival for some men.


STAMPEDE: Enzalutamide and Abiraterone Results

Check out the combination "Enzalutamide and Abiraterone Comparison" Results Summary Sheet and watch the video below.


STAMPEDE "M1 Radiotherapy Comparison" Results

Check out the "M1 Radiotherapy Comparison" Results Summary Sheet and watch one of the videos below (there is a full version and a shorter version):

Short version:


Full version:


STAMPEDE "Abiraterone Comparison" Results

Check out the "Abiraterone Comparison" Results Summary Sheet and watch the video below.


STAMPEDE: Docetaxel and Zoledronic Acid Results

Check out the "Docetaxel and Zoledronic Acid Comparisons" Results Summary Sheet and watch the video below.

When will more results be known?

New information may become available about the treatments patients receive during the study. If this happens, their study doctors will tell them about it and talk with them about whether they want to continue with treatment.

Further results are expected in the next few years from other treatments tested in STAMPEDE, which have now completed recruitment.

What do I need to know about the treatments still being tested?

Metformin: Metformin is a diabetic treatment that may also have an effect on prostate cancer growth and help prevent some of the side effects of hormone treatment. Only men without diabetes could join Treatment Group K, therefore all men who wished to take part needed to have a blood test to check for diabetes first.

Transdermal oestradiol: Hormone patches containing transdermal oestradiol are being assessed as an alternative form of hormone therapy. STAMPEDE is looking at whether transdermal oestradiol can work as well as, or better than, standard hormone therapy in treating the cancer longer-term. Men with diabetes could join this group, but men should have switched from standard hormone treatment to alternative patches soon after hormone treatment was first started.



Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

See the latest News in STAMPEDE through the link to the right.